Latest News about CYBN
Recent news which mentions CYBN
Cybin Touts Highlights of 'Transformative' Second-Quarter Performance
December 02, 2021
Tickers
CYBN
From Benzinga
Cybin Announces FDA Approvals, Participation in Conference
December 01, 2021
Tickers
CYBN
From Benzinga
Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
November 30, 2021
Tickers
CYBN
From Benzinga
Cybin Supports Psychedelic Treatment Clinic Through Grant
November 23, 2021
Tickers
CYBN
From Benzinga
NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved
November 23, 2021
Tickers
CYBN
From Benzinga
Cybin 'One Step Closer' to Creating Best Therapy for Mental Health
November 19, 2021
Tickers
CYBN
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
From Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
November 15, 2021
Tickers
CYBN
From Benzinga
Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser
November 14, 2021
Tickers
CYBN
From Benzinga
Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule'
November 11, 2021
Tickers
CYBN
From Benzinga
Cybin CEO Presenting at Jefferies London Healthcare Conference
November 11, 2021
Tickers
CYBN
From Benzinga
32 Stocks Moving in Tuesday's Pre-Market Session
November 09, 2021
From Benzinga
64 Biggest Movers From Yesterday
November 09, 2021
From Benzinga
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
November 08, 2021
Tickers
CYBN
From Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
November 08, 2021
From Benzinga
Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules
November 04, 2021
From Benzinga
Cybin Inc. Receives Schedule I Manufacturing License from DEA
November 04, 2021
Tickers
CYBN
From Benzinga
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
November 01, 2021
From Benzinga
Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex
October 27, 2021
Tickers
CYBN
From Benzinga
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
October 26, 2021
From Benzinga
These 4 Psychedelic Biotech Stocks Are Leading the Pack
October 26, 2021
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.